Mohamed Akoad to Antiviral Agents
This is a "connection" page, showing publications Mohamed Akoad has written about Antiviral Agents.
Connection Strength
0.253
-
Turgeon MK, Shah SA, Delman AM, Tran BV, Agopian VG, Wedd JP, Magliocca JF, Kim A, Cameron A, Olyaei A, Orloff SL, Anderson MP, Kubal CA, Cannon RM, Locke JE, Simpson MA, Akoad ME, Wongjirad CP, Emamaullee J, Moro A, Aucejo F, Feizpour CA, Vagefi PA, Nguyen MH, Esquivel CO, Dhanireddy K, Subramanian V, Chavarriaga A, Kazimi MM, Anderson MS, Sonnenday CJ, Kim SC, Foley DP, Abdouljoud M, Salgia RJ, Moris D, Sudan DL, Ganesh SR, Humar A, Doyle M, Chapman WC, Maithel SK. Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation. Ann Surg. 2021 10 01; 274(4):613-620.
Score: 0.149
-
Singh N, Wannstedt C, Keyes L, Mayher D, Tickerhoof L, Akoad M, Wagener MM, Cacciarelli TV. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts. Liver Transpl. 2008 Feb; 14(2):240-4.
Score: 0.058
-
Bennett FJ, Keilson JM, Turgeon MK, Oppat KM, Warren EAK, Shah SA, Agopian VG, Magliocca JF, Cameron A, Orloff SL, Kubal CA, Cannon RM, Akoad ME, Emamaullee J, Aucejo F, Vagefi PA, Nguyen MH, Dhanireddy K, Kazimi MM, Sonnenday CJ, Foley DP, Abdouljoud M, Sudan DL, Humar A, Doyle MBM, Chapman WC, Maithel SK. Racial Disparities in Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma. Ann Surg Oncol. 2025 Jan; 32(1):426-437.
Score: 0.046